Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
December 18 2023 - 8:00AM
Business Wire
– Becker is a serious neuromuscular condition
with no approved therapies –
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced the launch of an
educational website dedicated to the Becker muscular dystrophy
(Becker) community: www.beckermusculardystrophy.com. This is the
first website solely focused on providing Becker-specific resources
to help individuals and caregivers better understand the disease,
learn different approaches to care and stay up to date on advocacy
partnerships and available services.
Becker is a genetic disorder, mostly impacting males, with an
estimated 5,000 individuals living with the disease in the United
States. Individuals with Becker experience progressive muscle
degeneration and weakness due to contraction-induced muscle damage,
leading to the eventual loss of muscle function. Symptom onset can
occur at any age; once muscle loss begins, it is irreversible. Some
individuals living with Becker also experience heart failure from
cardiomyopathy, which may result in heart transplantation or early
death. There are currently no approved treatments for Becker and
limited supports and services are available for the Becker
community to help navigate living with the disease. The new Becker
website was launched to help fill this gap by offering a
comprehensive resource. It features educational content about the
disorder, such as diagnosis of Becker, symptoms, disease
progression, building a multi-disciplinary care team that considers
the multi-systemic nature of the disease, clinical trials and other
resources. In developing the website, Edgewise incorporated input
from the Becker community and patient advocacy organizations.
“The Becker journey can feel like you have no one to turn to, so
it's important to have information that is Becker specific to help
navigate the way,” said Nevin Steiner, a patient advocate living
with Becker. “I’m proud to be part of this outreach initiative. I
hope that sharing my voice and addressing the challenges we with
Becker face will help those that haven't progressed yet with Becker
better prepare for the future.”
“Ensuring that individuals with Becker and their loved ones feel
seen and heard while navigating a rare disease is so important,”
said Pat Furlong, Founder and CEO, Parent Project Muscular
Dystrophy. “Educational resources like Edgewise’s Becker website
are critical for these individuals when it comes to making informed
decisions around their care.”
“At Edgewise, we are committed to developing lifesaving
therapies for severe, rare muscle disorders,” said Joanne Donovan,
M.D., Ph.D., Chief Medical Officer of Edgewise. “Recognizing the
unmet need in Becker, a condition that for far too long has been
underserved, we are proud to provide a platform for the community
to foster support and education.”
Currently there is no cure for Becker; early and long-term
multidisciplinary care from neuromuscular specialists,
cardiologists, physical therapists, and other specialists is
critical for optimized disease management. Novel therapies are in
development for Becker, including muscle targeted interventions,
aimed at positively impacting disease trajectory.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in clinical trials in patients with
Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as
McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel
cardiac sarcomere modulator for the treatment of hypertrophic
cardiomyopathy and other disorders of cardiac diastolic
dysfunction. The entire team at Edgewise is dedicated to our
mission: changing the lives of patients and families affected by
serious muscle diseases. To learn more, go to: www.edgewisetx.com
or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram
and Threads.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference into this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218918378/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Oct 2023 to Oct 2024